Holen Sie sich die Stockscreener-App
65.06
1.48%
-0.98
Schlusskurs vom Vortag:
$66.04
Offen:
$65.71
24-Stunden-Volumen:
3.74M
Relative Volume:
1.92
Marktkapitalisierung:
$12.59B
Einnahmen:
$4.41B
Nettoeinkommen (Verlust:
$21.27M
KGV:
203.31
EPS:
0.32
Netto-Cashflow:
$288.81M
1W Leistung:
+1.27%
1M Leistung:
+7.66%
6M Leistung:
-12.78%
1J Leistung:
+13.54%
1-Tages-Spanne:
$63.93
$65.77
1-Wochen-Bereich:
$63.93
$66.26
52-Wochen-Spanne:
$53.56
$83.95
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
65.06 | 12.44B | 4.41B | 21.27M | 288.81M | 0.32 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report? - Yahoo Finance
Vitiligo Market Growth Trends and Forecast Report 2025-2033Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access - Yahoo Finance
Incyte (NASDAQ:INCY) Price Target Raised to $73.00 at Truist Financial - Defense World
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential - Investing.com
Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential By Investing.com - Investing.com India
Incyte to Present at Upcoming Investor Conference on Monday, June 9, 2025 at 11:20 am (ET) - BioSpace
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Incyte (INCY) Target Price Raised by Truist Securities | INCY St - GuruFocus
Incyte (INCY) Sees Price Target Boost from Truist Analyst | INCY Stock News - GuruFocus
Incyte to Present at Upcoming Investor Conference - Business Wire
Incyte Co. (NASDAQ:INCY) Shares Bought by Cetera Investment Advisers - Defense World
3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance
FDA approves Incyte’s retifanlimab combo for SCAC treatment - Yahoo Finance
Is Wall Street Bullish or Bearish on Incyte Stock? - inkl
Is Wall Street Bullish Or Bearish On Incyte Stock? - Barchart.com
Incyte Gets FDA Approval for Zynyz in New Cancer Indication - MSN
Incyte adds more FDA approvals for Zynyz in cancer - BioWorld MedTech
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Trea - GuruFocus
Incyte granted FDA approval of Zynyz for SCAC - The Pharma Letter
Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval - BioSpace
No Article III Appellate Standing Under the Sun - Lexology
FDA Broadens Approval for Incyte's Zynyz in Cancer Treatments (I - GuruFocus
FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Treatment | INCY Stock News - GuruFocus
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States | INCY Stock News - GuruFocus
FDA approves new anal cancer treatment Zynyz by Incyte - Investing.com
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States – Company AnnouncementFT.com - Financial Times
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - The Joplin Globe
Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show - Law.com
Incyte Corporation (INCY) Reaches Settlement with Novartis Over Royalty Dispute - GuruFocus
Incyte (INCY) Reaches $280M Settlement with Novartis Over Jakafi Royalties - GuruFocus
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Incyte settles royalty dispute with Novartis for $280 million - Investing.com
Incyte at Bank of America Conference: Strategic Insights on Growth - Investing.com
Incyte To Present At 2025 BofA Securities Health Care Conference; Webcast At 4:40 PM ET - Nasdaq
Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance - Yahoo Finance
Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating! - Smartkarma
Steroid Refactory Acute Graft-Versus-Host Disease Market Set - openPR.com
Incyte Co. (NASDAQ:INCY) Holdings Raised by Stifel Financial Corp - Defense World
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News
Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):